Detalhe da pesquisa
1.
Characterization of Viruses in Phase 3 and Phase 3b Trials (the Ring Study and the Dapivirine Ring Extended Access and Monitoring Trial) of the Dapivirine Vaginal Ring for Human Immunodeficiency Virus Type 1 Infection Risk Reduction.
Clin Infect Dis
; 76(6): 996-1002, 2023 03 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-36345569
2.
Clinical Presentation, Treatment Response, and Virology Outcomes of Women Who Seroconverted in the Dapivirine Vaginal Ring Trials-The Ring Study and DREAM.
Clin Infect Dis
; 76(3): 389-397, 2023 02 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-36189636
3.
First prospective comparison of genotypic versus phenotypic tropism assays in predicting virologic responses to maraviroc in a phase 3 study.
New Microbiol
; 42(2): 101-107, 2019 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-31034084
4.
Identification and Excision of a Fistulous Cesarean Scar Defect.
J Obstet Gynaecol Can
; 45(12): 102083, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36868350
5.
Characterizing the Diverse Mutational Pathways Associated with R5-Tropic Maraviroc Resistance: HIV-1 That Uses the Drug-Bound CCR5 Coreceptor.
J Virol
; 89(22): 11457-72, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26339063
6.
The maraviroc expanded access program - safety and efficacy data from an open-label study.
HIV Clin Trials
; 16(1): 10-21, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25777185
7.
Efficacy and safety of lersivirine versus etravirine for the treatment of HIV-1 infection in patients with prior non-nucleoside reverse transcriptase inhibitor (NNRTI) use and evidence of NNRTI resistance: a randomized phase 2B trial.
HIV Clin Trials
; 15(5): 209-17, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-25350959
8.
Characterization of resistance to the nonnucleoside NS5B inhibitor filibuvir in hepatitis C virus-infected patients.
Antimicrob Agents Chemother
; 56(3): 1331-41, 2012 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-22203605
9.
Safety, adherence, and HIV-1 seroconversion among women using the dapivirine vaginal ring (DREAM): an open-label, extension study.
Lancet HIV
; 8(2): e77-e86, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33539761
10.
Efficacy and safety of maraviroc versus efavirenz, both with zidovudine/lamivudine: 96-week results from the MERIT study.
HIV Clin Trials
; 11(3): 125-32, 2010.
Artigo
em Inglês
| MEDLINE | ID: mdl-20736149
11.
Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance.
J Antimicrob Chemother
; 64(2): 398-410, 2009 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-19515730
12.
Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naïve populations and associate with reduced treatment efficacy.
PLoS Med
; 5(7): e158, 2008 Jul 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-18666824
13.
Clonal analysis of HIV-1 genotype and function associated with virologic failure in treatment-experienced persons receiving maraviroc: Results from the MOTIVATE phase 3 randomized, placebo-controlled trials.
PLoS One
; 13(12): e0204099, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30586365
14.
Pharmacokinetics, Safety and Efficacy of Maraviroc in Treatment-experienced Pediatric Patients Infected With CCR5-Tropic HIV-1.
Pediatr Infect Dis J
; 37(5): 459-465, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29023357
15.
Rare selection of the K65R mutation in antiretroviral-naive patients failing a first-line abacavir/ lamivudine-containing HAART regimen.
Antivir Ther
; 11(6): 701-5, 2006.
Artigo
em Inglês
| MEDLINE | ID: mdl-17310814
16.
Once-daily maraviroc versus tenofovir/emtricitabine each combined with darunavir/ritonavir for initial HIV-1 treatment.
AIDS
; 30(8): 1229-38, 2016 05 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26854810
17.
First prospective comparison of genotypic vs phenotypic tropism assays in predicting virologic responses to Maraviroc (MVC) in a phase 3 study: MODERN.
J Int AIDS Soc
; 17(4 Suppl 3): 19519, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-25394028
18.
Incidence of CXCR4 tropism and CCR5-tropic resistance in treatment-experienced participants receiving maraviroc in the 48-week MOTIVATE 1 and 2 trials.
Antivir Chem Chemother
; 27: 2040206619895706, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31856576
19.
Burden of nonnucleoside reverse transcriptase inhibitor resistance in HIV-1-infected patients: a systematic review and meta-analysis.
AIDS Res Hum Retroviruses
; 30(8): 753-68, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-24925216
20.
Correlation between genotypic (V3 population sequencing) and phenotypic (Trofile ES) methods of characterizing co-receptor usage of HIV-1 from 200 treatment-naïve HIV patients screened for Study A4001078.
Antiviral Res
; 97(1): 60-5, 2013 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-23165088